Overview

Second Line Breast Cancer Trial

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole
Estradiol
Fulvestrant